Instrument Inactif

Communiqués Plicit Capital Corp Toronto S.E.

Actions

PLPh

CA7291431079

Recherche biotechnologique et médicale

Cours en clôture Toronto S.E.
-	-

16/07	Telo Genomics publie des données intérimaires positives issues de son essai clinique sur l'évaluation du risque de rechute basée sur l'instabilité génomique	CI
09/07	Telo Genomics dépose une demande de brevet pour protéger un nouvel algorithme de biomarqueurs TeloView dédié aux applications de la maladie résiduelle minimale par biopsie liquide dans le myélome multiple	CI

Communiqués

04/08	Telo Genomics Grants Stock Options	NE
16/07	Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment	NE
09/07	Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma	NE
27/06	Telo Genomics Announces Termination of Investor Relations Agreement	NE
14/04	Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma	NE
31/03	Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman	NE
09/03	Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing	NE
27/02	Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement	NE
18/02	Telo Genomics Closes First Tranche of Convertible Debentures Financing	NE
29/01	Telo Genomics Announces Appointment of John Price as Chief Financial Officer	NE
19/01	Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000	NE
18/12	Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program	NE
18/12	Telo Genomics : Presents Genomic Profiles of Peripheral Blood MRD Cells at ASH 2025December 11,2025	PU
11/12	Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting	NE
08/12	Telo Genomics : Presentation (693724f844f71419e21676d7 Telo Genomic Corp Deck December 2025)	PU
08/12	Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th	AQ
13/11	Telo Genomics to Present Groundbreaking Individual-Cell Risk Assessment MRD Technology at the Myeloma Canada MRD Implementation Summit 2025	NE
04/11	Telo Genomics : FS - 2025	PU
04/11	Telo Genomics : MD&A 2025	PU
22/10/25	Telo Genomics : Presentation (68f8eea167c23adf1ae768ed Telo Genomic Corp Deck October 2025)	PU
09/10/25	American Society of Hematology Accepts Telo Genomics' Abstract for Presentation at its 2025 Meeting and Exposition	NE
30/09/25	Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update	NE
19/09/25	Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting	NE
08/09/25	Telo Geonomics Announces Engagement of Investor Relations Service Provider	NE
05/08/25	Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference	NE